Another second-generation CAR construct incorporating CD28 signaling domain proved efficiency for 21 chemotherapy-resistant B precursor ALL patients (70% complete remission rate) without encountering prolonged B-cell aplasia after. This evidence concerns the gene CD28 and acute lymphoblastic leukemia.